You searched for: BioInvent
BioInvent publishes Phase I data for BI-1607
BioInvent receives EMA support for BI-1808
BioInvent has received a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) to grant BI-1808 orphan drug status...
BioInvent presents positive Phase I data for BI-1910
BioInvent has presented Phase I clinical data for BI-1910 at the Society for Immunotherapy of Cancer (SITC) 2025 scientific conference....
BioInvent presents Phase I data for BI-1910
BioInvent makes double presentations at ASH
BioInvent sharpens focus on its top clinical candidates
After a quarter of clinical progress, an increased operational focus on value-creating clinical programs and a strengthened financial position,...
BioInvent’s oncolytic virus showcased at ESMO
At the 2025 ESMO Congress, BioInvent International and Transgene presented new and encouraging clinical data for the oncolytic virus candidate BT-001....
BioInvent comments on the new chapter for BI-1206
BioInvent has initiated a phase IIa study with its antibody BI-1206 in combination with MSD's Keytruda. The study is aimed at...
BioInvent starts phase IIa study with BI-1206
BioInvent | Investing in Life Science 2025
CSO Björn Frendéus presents BioInvent at Investing in Life Science 2025.
BioInvent expands on its strategic portfolio shift
BioInvent has announced that it is reshaping its pipeline and focusing on its two most advanced clinical programs and pausing...
BioInvent pauses development – focuses on leading programs
BioInvent presents BT-001 data at ESMO
Monetization of future royalties increasingly popular
Monetization of royalties has become an increasingly popular financing option for biotech companies. The model, which involves so-called royalty aggregators, offers a...
BioInvent focuses on first-line treatment
BioInvent's Phase I dose-escalation study of BI-1206, in combination with MSD's pembrolizumab, shows promising clinical activity in heavily pretreated patients with...
BioInvent reports promising Phase I data for BI-1206
BioInvent secured up to $30 million from XOMA Royalty
BioInvent recently entered into a transaction with XOMA Royalty Corporation, in which the company sells its royalty and milestone rights for mezagitamab (TAK-079)...
BioInvent sells drug rights for millions
BioInvent International | Global Forum 2025
CSO Björn Frendéus presents BioInvent International at BioStock Global Forum 2025.
BioInvent receives FDA Fast Track Designation for BI-1808
BioInvent has published its interim report for Q1 2025, describing progress in the clinical programs. The company gained further momentum...
Takeda's milestone payment strengthens BioInvent's business model
BioInvent strengthens its position as a partner in antibody development. This is clear after global pharmaceutical giant Takeda has now initiated...
BioInvent's BI-1808 receives broad support from the FDA
BioInvent has achieved new success as the FDA has now granted orphan drug designation for BI-1808 for T-cell lymphoma (TCL), a broad category that...
BioInvent prepares for a data-rich 2025
As BioInvent turned the page on 2024, it was able to summarize a year of significant progress across its six clinical programs,...
BioInvent begins 2025 with positive clinical data
With several expected data readings from its four clinical programs, BioInvent has started 2025 on an encouraging note. The first...